Señales en vivo de COGT | Maximiza tus Ganancias con Getagraph.com

VENDER 106284 min ago

@ $8.60

Emitido: 14 feb 2024 @ 15:09

Retorno: -30.00%

Señal anterior: feb 14 - 12:47

Señal anterior: Comprar

Retorno: -2.05 %

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Stats
Volumen de hoy	912 095
Volumen promedio	2.15M
Capitalización de mercado	575.59M
EPS	$0 ( 2024-03-12 )
Próxima fecha de ganancias	( $-0.500 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.49
ATR14	$0.00500 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Ferrante Karen Jean	Buy	3 213	Stock Option (Right to Buy)
2024-03-28	Fairmount Funds Management Llc	Buy	286 851	Common Stock
2024-03-28	Fairmount Funds Management Llc	Buy	11 914	Series A Convertible Preferred Stock
2024-03-28	Fairmount Funds Management Llc	Sell	11 914	Series A Convertible Preferred Stock
2024-03-28	Fairmount Funds Management Llc	Sell	286 851	Common Stock

INSIDER POWER
88.05
Last 97 transactions
Buy: 19 542 341 \| Sell: 1 316 263

Volumen Correlación

Largo: -0.11 (neutral)

Corto: -0.48 (neutral)

Signal:(56.59) Neutral

Cogint Inc. Correlación

10 Correlaciones Más Positivas
NWL	0.911
CPIX	0.903
PRAX	0.9
CNDT	0.891
EWTX	0.89
QMCO	0.887
AQB	0.886
AVDX	0.886
SRTS	0.885
CHB	0.885

10 Correlaciones Más Negativas
PPBT	-0.881
FIZZ	-0.864
EPZM	-0.833
SNCR	-0.822
XOG	-0.821
TYHT	-0.816
LEDS	-0.805

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cogint Inc. Correlación - Moneda/Commodity

-0.49
( neutral )

-0.51
( weak negative )

0.00
( neutral )

0.44
( neutral )

Cogint Inc. Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-3.59M (0.00 %)
EPS:	$-2.42

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-3.59M (0.00 %)
EPS:	$-2.42

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-5.88M (0.00 %)
EPS:	$-2.26

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.814

Financial Reports:

No articles found.

Cogint Inc.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.